Oncologists
MA
Boston, MA
Dr. Levi Garraway, MD

Dr. Levi Garraway, MD

Medical Oncology

Dr. Levi Garraway, MD is a medical oncologist in Boston, MA. He graduated from HARVARD Medical School in 1999. He is accepting new patients.

Practice

44 Binney St Boston, MA 02115

Make an Appointment

(617) 632-6689

Save money with free prescription discounts

Get your prescription for as low as $4 with our free coupons or discount card, usable at over 64,000 participating pharmacies.

Optum Perks and Healthgrades are subsidiaries of RVO Health.

Experience Check

Search for experience in a specific area

Condition or Procedure

Learn more about experience and why treatment frequency matters

Insurance Check

Search for your insurance carrier and choose your plan type

Insurance Carrier

Dr. Garraway's Reviews

Know Before You Go

What to Expect at Your First Appointment With a Breast Cancer Specialist
Gallbladder Cancer Explained
4 Oncologist Tips for People With Metastatic Breast Cancer

Overall Patient Satisfaction

About Me

biography

Dr. Levi Garraway, MD is a medical oncologist in Boston, MA. He graduated from HARVARD Medical School in 1999. He is accepting new patients.

Medical Oncology

Massachusetts General Hospital
Residency Hospital
Massachusetts General Hospital
Internship Hospital
Harvard Medical School
Medical School, 1999

For detailed information about any of the below board actions, please search for the provider's records on the linked state licensing board or the Federation of State Medical Boards. To learn more about the difference between these sources, please refer to our FAQs.

Healthgrades has not received any data indicating a board action exists for this provider.

Healthgrades receives board action history for physicians and physician assistants. The information displayed here is sourced from independent information providers, such as state board websites, and may not be the most up-to-date information. Healthgrades makes no representations with respect to the accuracy of any information provided here and assumes no responsibility or liability for such information.

Learn more about medical license public record check

Long-term drug administration in the adult zebrafish using oral gavage for cancer preclinical studies, 2016-07-01
Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine, 2014-05-18
The landscape of somatic copy-number alteration across human cancers, 2010-02-18
Genetic mechanisms of immune evasion in colorectal cancer, 2018-03-06
Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma, 2010-11-25
Inferring Loss-of-Heterozygosity from Unpaired Tumors Using High-Density Oligonucleotide SNP Arrays, 2006-05-12
Punctuated Evolution of Prostate Cancer Genomes, 2013-04-25
Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behavior, and phenotypic associations of resistance mechanisms, 2015-11-19
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors, 2017-11-06
The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity, 2012-03-28
Binding of TMPRSS2-ERG to BAF chromatin remodeling complexes mediates prostate oncogenesis, 2018-08-02
MicroSCALE Screening Reveals Genetic Modifiers of Therapeutic Response in Melanoma, 2012-05-15
High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines, 2016-02-29
Highly recurrentTERTpromoter mutations in human melanoma, 2013-01-24
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma, 2013-11-21
Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival, 2020-07-20
High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing, 2011-11-07
Global chromatin profiling revealsNSD2mutations in pediatric acute lymphoblastic leukemia, 2013-09-29
Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy, 2010-07-04
Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer, 2014-10-02
Cancer-germline antigen expression discriminates clinical outcome to CTLA-4 blockade, 2018-04-12
MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability inBRAF,NRAS, andNF1mutant melanomas, 2019-02-01
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib, 2014-03-13
Genomic sequencing of colorectal adenocarcinomas identifies a recurrentVTI1A-TCF7L2fusion, 2011-09-04
Sequence analysis of mutations and translocations across breast cancer subtypes, 2012-06-20
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition, 2013-11-03
PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration Resistant Prostate Cancer, is a Mediator of Resistance to Androgen Deprivation Therapy, 2015-03-25
Erratum to: Unraveling the clonal hierarchy of somatic genomic aberrations, 2017-05-02
RNF43 is frequently mutated in colorectal and endometrial cancers, 2014-10-26
Colorectal Cancers from Distinct Ancestral Populations Show Variations inBRAFMutation Frequency, 2013-09-16
Phenotypic characterization of a comprehensive set ofMAPK1/ERK2 missense mutants, 2016-10-18
Unraveling the clonal hierarchy of somatic genomic aberrations, 2014-08-26
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma, 2016-04-14
Genomic copy number dictates a gene-independent cell response to CRISPR-Cas9 targeting, 2016-06-03
Reduced local mutation density in regulatory DNA of cancer genomes is linked to DNA repair, 2013-12-15
AKT-independent signaling downstream of oncogenicPIK3CAmutations in human cancer, 2009-07-07
Melanoma genome sequencing reveals frequentPREX2mutations, 2012-05-09
The genomic complexity of primary human prostate cancer, 2011-02-10
COT/MAP3K8drives resistance to RAF inhibition through MAP kinase pathway reactivation, 2010-11-24
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq, 2016-04-08
An oncogenic role forETV1in melanoma, 2010-02-16
Integrative analysis of proteomic signatures, mutations and drug responsiveness in the NCI 60 cancer cell line set, 2010-02-02
Exome sequencing of African-American prostate cancer reveals loss-of-functionERFmutations, 2017-05-17
SomaticERCC2mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma, 2014-08-05
Fusobacterium nucleatumand T-cells in Colorectal Carcinoma, 2015-08-01
Assessing the clinical utility of cancer genomic and proteomic data across tumor types, 2014-06-22
A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer, 2015-03-09
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine, 2016-07-26
An Integrated Approach to Uncover Drivers of Cancer, 2010-12-02
Discovery and saturation analysis of cancer genes across 21 tumor types, 2014-01-05
A Landscape of Driver Mutations in Melanoma, 2012-07-20
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer, 2012-05-20
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma, 2011-07-28
The SETDB1 histone methyltransferase is recurrently amplified in and accelerates melanoma, 2011-03-24
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T cell Therapy, 2018-04-05
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers, 2013-04-25
Systematic genomic and translational efficiency studies of uveal melanoma, 2017-06-08
Defining a Cancer Dependency Map, 2017-07-27
Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine, 2018-06-14
PTR1-dependent synthesis of tetrahydrobiopterin contributes to oxidant susceptibility in the trypanosomatid protozoan parasiteLeishmania major, 2009-04-25
Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state, 2017-01-09
TRIM24 is an oncogenic transcriptional activator in prostate cancer, 2016-05-26
Mutational heterogeneity in cancer and the search for new cancer genes, 2013-06-16
Major copy proportion analysis of tumor samples using SNP arrays, 2008-04-21
Discordant cellular response to pre-surgical letrozole in bilateral synchronous ER+ breast cancers with aKRASmutation orFGFR1gene amplification, 2012-08-09
Genotyping Cancer-Associated Genes in Chordoma Identifies Mutations in Oncogenes and Areas of Chromosomal Loss Involving CDKN2A, PTEN, and SMARCB1, 2014-07-01
Molecular Archeology: Unearthing Androgen Induced Structural Rearrangements in Prostate Cancer Genomes, 2013-02-11
Functional genomics reveals serine synthesis is essential in PHGDH-amplified breast cancer, 2011-08-18
Fusobacterium nucleatumin colorectal carcinoma tissue and patient prognosis, 2015-08-26
The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer, 2020-05-13
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples, 2009-11-18
Genomic heterogeneity and exceptional response to dual pathway inhibition in anaplastic thyroid cancer, 2016-10-17
Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection, 2014-01-14
Long-term benefit of PD-L1 blockade in lung cancer associated withJAK3activation, 2015-05-26
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition, 2013-11-21
Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts, 2009-10-16
MTAPdeletion confers enhanced dependency on the arginine methyltransferase PRMT5 in human cancer cells, 2016-02-11